One of the UK’s largest initiatives for combating antimicrobial resistance, Pathways to Antimicrobial Clinical Efficacy (PACE), has announced up to £6 million in funding to drive new research. This funding will support the development of novel therapies for serious bacterial infections.
“This latest funding round reflects our commitment to support the most innovative global research in AMR, and we’re excited that we can now support even more pioneering projects that have the potential to save lives and protect future generations from drug-resistant infections,” said Beverley Isherwood, Programme Director of PACE.
This is the third PACE funding round aimed at supporting innovative therapeutic projects. The initiative focuses on accelerating early-stage drug and diagnostic development targeting resistant bacterial infections with the highest global health burden.
The call is designed to fill a critical gap in the development pipeline and foster advancements that address antimicrobial resistance effectively.
https://sciencebusiness.net/news/r-d-funding/antimicrobial-resistance/funding-radar-uk-and-eu-bring-forward-antimicrobial-resistance
